Peripheral Neuropathy Treatment Denied by Insurance? How to Appeal

Peripheral neuropathy — damage to the peripheral nerves causing numbness, tingling, pain, and weakness — affects more than 20 million Americans. It has many causes: diabetes, chemotherapy, autoimmune disease, nutritional deficiency, and hereditary conditions. Insurance denials are common for nerve conduction studies, medications like gabapentin and Lyrica (pregabalin), and IVIG for autoimmune forms like CIDP. This guide covers the key denial scenarios and how to fight back.

Common Denial Reasons for Peripheral Neuropathy Treatment

Nerve conduction study (NCS/EMG) denied — Electromyography and nerve conduction studies are the primary diagnostic tool for peripheral neuropathy. Insurers may deny them citing insufficient clinical documentation of symptoms, or argue that the primary care physician should diagnose neuropathy clinically without electrodiagnostic testing.

Lyrica (pregabalin) denied — Pregabalin is FDA-approved specifically for diabetic peripheral neuropathy and postherpetic neuralgia. Despite FDA approval, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements and step therapy (requiring failure of gabapentin first) are common.

Gabapentin quantity limits — Some plans impose daily dose limits on gabapentin (e.g., limiting to 1800 mg/day when patients require up to 3600 mg/day). Dose-limiting restrictions impair pain control.

IVIG for CIDP denied — Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune neuropathy that responds to IVIG, corticosteroids, and plasma exchange. IVIG for CIDP is frequently denied for: insufficient diagnostic documentation, failure to confirm the diagnosis with nerve conduction studies and nerve biopsy, dosing disputes, and denial of maintenance IVIG after initial response.

Skin punch biopsy for small fiber neuropathy denied — Small fiber neuropathy (SFN) affects only unmyelinated sensory fibers and does not show on standard NCS. Skin punch biopsy for intraepidermal nerve fiber density (IENFD) is the diagnostic test — but insurers may deny it as "experimental" despite established use.

Referral to neurologist denied — Some plans restrict neurology referrals for peripheral neuropathy, arguing that primary care management is sufficient.

Clinical Frameworks Supporting Your Appeal

AAN Clinical Practice Guidelines for Diabetic Neuropathy — The AAN recommends: NCS for evaluation of peripheral neuropathy, pregabalin as a first-line agent with Level A evidence for painful diabetic peripheral neuropathy (DPN), and duloxetine and tapentadol as alternative Level A options. Gabapentin and tricyclic antidepressants have Level B evidence. If you need pregabalin for diabetic neuropathy, cite AAN Level A evidence.

AAN CIDP Guideline — The AAN recommends IVIG, corticosteroids, and plasma exchange for CIDP with Class I evidence. EFNS/PNS diagnostic criteria for CIDP include clinical features plus electrodiagnostic confirmation (nerve conduction studies showing demyelination pattern). For IVIG maintenance in CIDP, document response to induction treatment and relapse upon dose reduction.

EFNS/PNS CIDP Diagnostic Criteria — CIDP diagnosis requires: progressive or relapsing weakness of limbs, absent or reduced deep tendon reflexes, onset >2 months, and electrodiagnostic evidence of demyelination (prolonged distal latencies, reduced conduction velocities, conduction block, prolonged F-waves). Submit the NCS report with specific quantitative values meeting criteria.

Small Fiber Neuropathy — SFN is increasingly recognized as a distinct entity causing burning pain, autonomic symptoms, and impaired quality of life. Skin punch biopsy showing reduced IENFD is the diagnostic standard. The AAN and several academic centers accept skin biopsy as an appropriate diagnostic tool. If denied, cite published AAN guidance and the fact that SFN cannot be diagnosed by standard NCS.

Painful Diabetic Neuropathy — FDA Approval — Pregabalin (Lyrica) has FDA-approved labeling specifically for "management of neuropathic pain associated with diabetic peripheral neuropathy." FDA-approved indications cannot be denied as "experimental." If step therapy is imposed, document gabapentin trial outcome.

Step-by-Step Appeal Strategy

Step 1: For NCS/EMG denials. Provide clinical documentation of neuropathy symptoms: describe the distribution, character (burning, stabbing, numbness), duration, and functional impact. Identify the suspected etiology (diabetes, chemotherapy, autoimmune). NCS/EMG is necessary to confirm the diagnosis, characterize the neuropathy type (axonal vs. demyelinating), and guide treatment — all of which are medically necessary for proper management.

Step 2: For Lyrica after gabapentin step therapy. Document the gabapentin trial: dose attempted (ideally titrated to at least 1800 mg/day), duration, degree of pain relief (use numeric pain scale), and reason for transition (inadequate efficacy, side effects). NRS pain score ≥4 despite maximized gabapentin supports need for Lyrica.

Step 3: For CIDP IVIG appeals. Submit complete NCS report demonstrating demyelinating pattern, EFNS/PNS criteria documentation, neurologist notes documenting clinical diagnosis, and prior treatment response data. For maintenance IVIG, document that dose reduction or discontinuation caused clinical relapse.

Step 4: For IVIG dosing disputes. Standard CIDP induction IVIG dosing is 2 g/kg, followed by maintenance at 1 g/kg every 3 weeks (or individualized). If the insurer is restricting dose or frequency below the clinical protocol, document the neurologist's dosing rationale and note that inadequate dosing leads to CIDP relapse.

Step 5: For skin biopsy (SFN). Document that standard NCS is normal (confirming this is small fiber involvement, not large fiber), describe the burning pain and autonomic symptoms that are consistent with SFN, and note that skin biopsy is the recognized diagnostic standard for SFN in clinical practice guidelines.

Step 6: File internal appeal with neurology support. A board-certified neurologist's Letter of Medical Necessity carries significant weight for all neuropathy appeals. Escalate to External Independent Review: Complete Guide" class="auto-link">external review for continued denials — neuropathy is well-defined and external reviewers apply AAN guidelines.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN is a common complication of platinum-based chemotherapy (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and vinca alkaloids (vincristine). CIPN is recognized by the American Society of Clinical Oncology (ASCO) as a clinically significant toxicity. Duloxetine has Level A evidence for CIPN pain management. If your CIPN treatment was denied, cite ASCO clinical practice guidelines on CIPN management and document your chemotherapy regimen and neuropathy symptoms.

Fight Back With ClaimBack

Peripheral neuropathy causes real pain and real disability. Insurance barriers should not prevent you from accessing appropriate diagnostic testing and treatment. ClaimBack helps you build an appeal that documents your symptoms, NCS findings, and the clinical guidelines supporting your treatment.

Start your peripheral neuropathy appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied